You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Implantation of Bioengineered Intrinsically Innervated Internal Anal Sphincter BioSphincter to Treat Fecal Incontinence

    SBC: CELLF-BIO LLC            Topic: 300

    DESCRIPTION provided by applicant We propose to bring to market a novel regenerative medicine based therapy for fecal incontinence FI FI is the recurrent uncontrolled passage of fecal material The Internal Anal Sphincter IAS is responsible for maintaining anorectal continence Function of the IAS is dependent upon the neuromuscular integrity of both the smooth muscle and the intrinsic en ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Delivery of peptides for inducing voiding associated with neurological retention

    SBC: Dignify Therapeutics LLC            Topic: 106

    Abstract Neurological conditions such as multiple sclerosis Parkinson s disease dementia spina bifida diabetes stroke and spinal cord injury SCI can result in loss of voluntary voiding of urine and require intermittent bladder catheterization for voiding Catheter use is associated with increased incidence of health problems predominately repeated urinary tract infections sepsis ureth ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  3. New generation of catheters for treatment of atrial fibrillation

    SBC: NOCTURNAL PRODUCT DEVELOPMENT, LLC            Topic: NHLBI

    DESCRIPTION provided by applicant Atrial fibrillation AF remains the most commonly occurring cardiac arrhythmia It is associated with a lower quality of life and a higher rate of morbidity andamp mortality primarily due to poor hemodynamics and often stroke One of the main options to treat atrial fibrillation is to ablate abnormal sources of electrical activity using percutaneous radiofrequ ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  4. New Class of Bright Sharp Tunable Near Infrared Fluorophores for Flow Cytometry

    SBC: Nirvana Sciences, Inc.            Topic: R

    DESCRIPTION provided by applicant Polychromatic flow cytometry FC is one of the most powerful analytical techniques routinely used by both basic research and clinical diagnostics laboratories for the immunological categorization of cells Dyes used for FC typically exhibit broad fluorescent emission bands with full width at half maximum fwhm values of nm This limits the maximum numbe ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Nomethiazoles harnessing GABA and NO mimetic activity for Alzheimer s therapy

    SBC: sGC Pharma Inc.            Topic: NIA

    DESCRIPTION provided by applicant Alzheimerandapos s disease AD occurs in one out of eight Americans of age and affects of the elderly over Current FDA approved drugs provide short term symptomatic relief of AD There is a pressing need to discover new disease modifying medications AD is multifactorial in origin and progression A drug attenuating several underlying factors is a p ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  6. The CellRaft AIR System Workflow Automation for Stem Cell Isolation and Recovery

    SBC: CELL MICROSYSTEMS INC            Topic: 200

    DESCRIPTION provided by applicant Stem cell research is an emerging field with the promise of creating dramatic new approaches for disease treatment and drug discovery The research and regenerative medicine market space for stem cells is one of the most dynamic areas in the life science industry today Globally the stem cell market is growing at a CAGR of and will reach an approximate ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  7. A Rapid assay for RNA targeted drugs: Instrumentation Supplement

    SBC: NUBAD LLC            Topic: 300

    DESCRIPTION provided by applicant Some of the most significant therapies that treat disease target nucleic acids Drugs that target nucleic acid include cancer drugs antibiotics and antivirals Combined these classes of drugs have annual sales worldwide of $ billion Antibiotics that target nucleic acids account for $ billion of the $ billion of sales annuall for all antibiotics an ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Measurement of Beta Cell Death in Diabetes

    SBC: L2 DIAGNOSTICS LLC            Topic: 200

    DESCRIPTION provided by applicant All forms of diabetes are characterized by the death of insulin producing cells In Type diabetes T D this leads to the reliance on exogenous insulin for survival Death of cells is silent it cannot be detected in vivo until it has progressed to such an extent that metabolic function is impaired The loss of cells has only been assessed by functiona ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  9. A Quantitative Optical Sensor to Monitor Tumor Vascular Physiology

    SBC: Zenalux Biomedical, Inc.            Topic: 102

    DESCRIPTION provided by applicant In there were new cases of head and neck cancers HNC in the United States Early detection of new and locally recurrent cancers is clinically important to reduce not only cancer related mortality but also treatment associated morbidity as it impacts multiple organ functions including respiration olfaction hearing eating swallowing and speak ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Anti-biofilm agents for the treatment of pulmonary infection in cystic fibrosis p

    SBC: AGILE SCIENCES, INC.            Topic: NIAID

    DESCRIPTION provided by applicant The leading cause of mortality in patients with cystic fibrosis CF is pulmonary failure from lung infections and the predominant organism isolated from these infections is the bacterium Pseudomonas aeruginosa Lung infections of CF patients persist over the lifetime of the patients and are impossible to eradicate due to the ability of bacteria to form biofi ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government